Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (British Journal of Cancer, (2019), 120, 10, (959-967), 10.1038/s41416-019-0435-4)

on behalf of the SOLE Investigators

doi:10.1038/s41416-019-0709-x

Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (British Journal of Cancer, (2019), 120, 10, (959-967), 10.1038/s41416-019-0435-4)

on behalf of the SOLE Investigators

International Breast Cancer Study Group (IBCSG) Coordinating Center
Dana-Farber Cancer Institute
European Institute of Oncology
Sahlgrenska University Hospital
Monash University
Luzerner Kantonsspital
University Hospital of Liège
University Hospital Gasthuisberg
IRCCS Centro Di Riferimento Oncologico Aviano
Instituto Nacional de Enfermedades Neoplásicas Eduardo Cáceres Graziani
Swiss Group for Clinical Cancer Research
Griffith University
Prevention and Clinical Network (ISPRO)
Chilean Cooperative Group for Oncologic Research (GOCCHI)
CHR Verviers
CHC Clinique St. Joseph
University of Bern
University of Melbourne
Karolinska Institutet
University of Geneva and Geneva University Hospitals
Ospedale Centrale di Bolzano
Sandton Oncology Centre
Harvard Medical School
University of Sydney

Research output: Contribution to journal › Comment/debate

Abstract

The ClinicalTrials.gov Identifier was incorrectly listed as NCT00651456. The correct identifier is listed below. Clinical trial information Clinical trial information: NCT00553410.

Original language	English
Pages (from-to)	1119
Number of pages	1
Journal	British Journal of Cancer
Volume	122
Issue number	7
DOIs	https://doi.org/10.1038/s41416-019-0709-x
State	Published - 31 Mar 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41416-019-0709-x

Fingerprint

Dive into the research topics of 'Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (British Journal of Cancer, (2019), 120, 10, (959-967), 10.1038/s41416-019-0435-4)'. Together they form a unique fingerprint.

Cite this

on behalf of the SOLE Investigators (2020). Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (British Journal of Cancer, (2019), 120, 10, (959-967), 10.1038/s41416-019-0435-4). British Journal of Cancer, 122(7), 1119. https://doi.org/10.1038/s41416-019-0709-x

@article{6f9aa1e825214934a463b87a8d09763c,

title = "Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (British Journal of Cancer, (2019), 120, 10, (959-967), 10.1038/s41416-019-0435-4)",

abstract = "The ClinicalTrials.gov Identifier was incorrectly listed as NCT00651456. The correct identifier is listed below. Clinical trial information Clinical trial information: NCT00553410.",

author = "\{on behalf of the SOLE Investigators\} and Karin Ribi and Weixiu Luo and Marco Colleoni and Per Karlsson and Jacquie Chirgwin and Stefan Aebi and Guy Jerusalem and Patrick Neven and \{Di Lauro\}, Vincenzo and Gomez, \{Henry L.\} and Thomas Ruhstaller and Ehtesham Abdi and Laura Biganzoli and Bettina M{\"u}ller and Annelore Barbeaux and Graas, \{Marie Pascale\} and Manuela Rabaglio and Francis, \{Prudence A.\} and Theodoros Foukakis and Olivia Pagani and Claudio Graiff and Daniel Vorobiof and Rudolf Maibach and \{Di Leo\}, Angelo and Gelber, \{Richard D.\} and Aron Goldhirsch and Coates, \{Alan S.\} and Regan, \{Meredith M.\} and J{\"u}rg Bernhard",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to Cancer Research UK.",

year = "2020",

month = mar,

day = "31",

doi = "10.1038/s41416-019-0709-x",

language = "Ingl{\'e}s",

volume = "122",

pages = "1119",

journal = "British Journal of Cancer",

issn = "0007-0920",

number = "7",

}

on behalf of the SOLE Investigators 2020, 'Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (British Journal of Cancer, (2019), 120, 10, (959-967), 10.1038/s41416-019-0435-4)', British Journal of Cancer, vol. 122, no. 7, pp. 1119. https://doi.org/10.1038/s41416-019-0709-x

Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (British Journal of Cancer, (2019), 120, 10, (959-967), 10.1038/s41416-019-0435-4). / on behalf of the SOLE Investigators.
In: British Journal of Cancer, Vol. 122, No. 7, 31.03.2020, p. 1119.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction

T2 - Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (British Journal of Cancer, (2019), 120, 10, (959-967), 10.1038/s41416-019-0435-4)

AU - on behalf of the SOLE Investigators

AU - Ribi, Karin

AU - Luo, Weixiu

AU - Colleoni, Marco

AU - Karlsson, Per

AU - Chirgwin, Jacquie

AU - Aebi, Stefan

AU - Jerusalem, Guy

AU - Neven, Patrick

AU - Di Lauro, Vincenzo

AU - Gomez, Henry L.

AU - Ruhstaller, Thomas

AU - Abdi, Ehtesham

AU - Biganzoli, Laura

AU - Müller, Bettina

AU - Barbeaux, Annelore

AU - Graas, Marie Pascale

AU - Rabaglio, Manuela

AU - Francis, Prudence A.

AU - Foukakis, Theodoros

AU - Pagani, Olivia

AU - Graiff, Claudio

AU - Vorobiof, Daniel

AU - Maibach, Rudolf

AU - Di Leo, Angelo

AU - Gelber, Richard D.

AU - Goldhirsch, Aron

AU - Coates, Alan S.

AU - Regan, Meredith M.

AU - Bernhard, Jürg

PY - 2020/3/31

Y1 - 2020/3/31

N2 - The ClinicalTrials.gov Identifier was incorrectly listed as NCT00651456. The correct identifier is listed below. Clinical trial information Clinical trial information: NCT00553410.

AB - The ClinicalTrials.gov Identifier was incorrectly listed as NCT00651456. The correct identifier is listed below. Clinical trial information Clinical trial information: NCT00553410.

UR - https://www.scopus.com/pages/publications/85078623828

U2 - 10.1038/s41416-019-0709-x

DO - 10.1038/s41416-019-0709-x

M3 - Comentario/Debate

C2 - 31949268

AN - SCOPUS:85078623828

SN - 0007-0920

VL - 122

SP - 1119

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 7

ER -

on behalf of the SOLE Investigators. Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (British Journal of Cancer, (2019), 120, 10, (959-967), 10.1038/s41416-019-0435-4). British Journal of Cancer. 2020 Mar 31;122(7):1119. doi: 10.1038/s41416-019-0709-x

Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (British Journal of Cancer, (2019), 120, 10, (959-967), 10.1038/s41416-019-0435-4)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this